Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.11−0.11 (-3.42%)
Close on Nov 13, 2026Market cap $538.47MP/E –Yield –
Entera Bio operating margin
Operating margin is operating income as a percentage of revenue.
Entera Bio's operating margin for the twelve months ending Dec 31, 2025 was -27450.0%. For fiscal 2025 it was -27450.0%, against -5295.6% the year before. The highest annual figure on record is -2139.6% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -27450.0% | −22154.4 |
| FY2024 | Dec 31, 2024 | -5295.6% | +4418.6 |
| FY2022 | Dec 31, 2022 | -9714.2% | −7574.6 |
| FY2021 | Dec 31, 2021 | -2139.6% | +920.1 |
| FY2020 | Dec 31, 2020 | -3059.7% | +1793.7 |
| FY2019 | Dec 31, 2019 | -4853.4% | −2681.2 |
| FY2018 | Dec 31, 2018 | -2172.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -6102.4% | +15811.9 |
| Q4 FY2024 | Dec 31, 2024 | -2850.0% | +32962.5 |
| Q3 FY2024 | Sep 30, 2024 | -7192.9% | +191.2 |
| Q2 FY2024 | Jun 30, 2024 | -3798.2% | +1841.5 |
| Q4 FY2022 | Dec 31, 2022 | -21914.3% | −19436.7 |
| Q3 FY2022 | Sep 30, 2022 | -35812.5% | −33512.5 |
| Q2 FY2022 | Jun 30, 2022 | -7384.1% | −5026.3 |
| Q1 FY2022 | Mar 31, 2022 | -5639.7% | −4149.9 |
| Q4 FY2021 | Dec 31, 2021 | -2477.6% | +4305.1 |
| Q3 FY2021 | Sep 30, 2021 | -2300.0% | +441.9 |
| Q2 FY2021 | Jun 30, 2021 | -2357.8% | – |
| Q1 FY2021 | Mar 31, 2021 | -1489.8% | – |
| Q2 FY2020 | Jun 30, 2020 | -6782.7% | – |
| Q2 FY2019 | Jun 30, 2019 | -2741.9% | – |
See a number that looks wrong?